| Revista: | Anales médicos (México, D.F.) |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000319363 |
| ISSN: | 0185-3252 |
| Autores: | Soria Céspedes, Danny1 Ortiz Hidalgo, Carlos |
| Instituciones: | 1Centro Médico ABC, Departamento de Patología, México, Distrito Federal. México |
| Año: | 2008 |
| Periodo: | Jul-Sep |
| Volumen: | 53 |
| Número: | 3 |
| Paginación: | 149-153 |
| País: | México |
| Idioma: | Español |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico |
| Resumen en español | puede ser usada para que clínicamente sean éstos clasificados de una manera más precisa |
| Resumen en inglés | Breast carcinoma is a complex group of distinct biological entities with specific pathologic features and biological behavior. Tumor type, tumor size, tumor grade, margin and nodal status along with estrogen receptors, progesterone receptors and Her2/neu expression are used to determine patient treatment and predict prognosis. Studying gene profiling for invasive breast carcinoma, Perou et al. have classified mammary carcinoma into five subtypes: 1) Her2/neu over expressing, 2) luminal A, 3) luminal B, 4) basal-like and 5) normal-like. These groups may also be identified using immunohistochemistry. The importance of this classification is the difference in clinical outcomes, with Her2/neu over expressing and basal-like, associated with poor prognosis. Recently genome research has provided evidence that the molecular features of individual breast cancer may have important implications for prognosis and therapeutic decisions. A multigene assay has been developed, that predicts recurrence and assesses the benefit from chemotherapy in a subset of patients with breast carcinoma. The 21 gene assay known as Oncotype DX® (Genomic Health) is a clinically validated laboratory test, that predicts the likelihood of breast cancer recurrence in women with newly diagnosed, early stage, (estrogen receptor positive and lymph node negative), invasive breast cancer. Oncotype DX® analyzes a specific set of genes within a tumor to determine a recurrence score that corresponds to a specific likelihood of breast cancer recurrence within 10 years of the initial diagnosis. The test measures the expression of each gene by quantitative RT-PCR using RNA from formalin-fixed, paraffin embedded tissue. Molecular genetic will provide a better understanding of the biology of individual tumors, and this information can be used to more accurately classify them in a clinically relevant manner |
| Disciplinas: | Medicina |
| Palabras clave: | Diagnóstico, Oncología, Genética, Cáncer, Mama, Genética molecular, Pronóstico, Recurrencia, Clasificación, Expresión génica, Carcinoma |
| Keyword: | Medicine, Diagnosis, Oncology, Cancer, Breast, Molecular genetics, Prognosis, Recurrence, Classification, Gene expression, Carcinoma, Genetics |
| Texto completo: | Texto completo (Ver PDF) |
